RS55641B1 - Dijagnostičko sredstvo interferon tipa 1 - Google Patents

Dijagnostičko sredstvo interferon tipa 1

Info

Publication number
RS55641B1
RS55641B1 RS20170089A RSP20170089A RS55641B1 RS 55641 B1 RS55641 B1 RS 55641B1 RS 20170089 A RS20170089 A RS 20170089A RS P20170089 A RSP20170089 A RS P20170089A RS 55641 B1 RS55641 B1 RS 55641B1
Authority
RS
Serbia
Prior art keywords
interferon
diagnostic
type
interferon diagnostic
Prior art date
Application number
RS20170089A
Other languages
English (en)
Inventor
Brandon Higgs
Wei Zhu
Chris Morehouse
Barbara White
Bahija Jallal
Yihong Yao
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of RS55641B1 publication Critical patent/RS55641B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RS20170089A 2009-09-03 2010-09-02 Dijagnostičko sredstvo interferon tipa 1 RS55641B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23963009P 2009-09-03 2009-09-03
PCT/US2010/047721 WO2011028933A1 (en) 2009-09-03 2010-09-02 Type 1 interferon diagnostic

Publications (1)

Publication Number Publication Date
RS55641B1 true RS55641B1 (sr) 2017-06-30

Family

ID=43649646

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170089A RS55641B1 (sr) 2009-09-03 2010-09-02 Dijagnostičko sredstvo interferon tipa 1

Country Status (23)

Country Link
US (3) US20120251546A1 (sr)
EP (1) EP2473636B1 (sr)
JP (2) JP5727484B2 (sr)
KR (1) KR20120101340A (sr)
CN (1) CN102753704A (sr)
AU (1) AU2010289383B2 (sr)
BR (1) BR112012004781A2 (sr)
CA (1) CA2772921A1 (sr)
CY (1) CY1118566T1 (sr)
DK (1) DK2473636T3 (sr)
ES (1) ES2613055T3 (sr)
HR (1) HRP20170091T1 (sr)
HU (1) HUE032917T2 (sr)
LT (1) LT2473636T (sr)
ME (1) ME02599B (sr)
MX (1) MX2012002640A (sr)
PL (1) PL2473636T3 (sr)
PT (1) PT2473636T (sr)
RS (1) RS55641B1 (sr)
RU (1) RU2012112802A (sr)
SI (1) SI2473636T1 (sr)
SM (1) SMT201700063B (sr)
WO (1) WO2011028933A1 (sr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050040866A (ko) * 2002-06-11 2005-05-03 아이다호 리서치 파운데이션 바이러스 감염의 검출을 위한 ⅰ형 인터페론-유도성 단백질
BRPI0719912A2 (pt) * 2006-12-06 2014-03-04 Medimmune Llc Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico
EP2068924A4 (en) * 2007-05-03 2011-07-20 Medimmune Llc INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS
WO2012149228A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CN111494624A (zh) * 2012-06-13 2020-08-07 阿斯特拉捷利康股份公司 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案
JP6531306B2 (ja) * 2015-02-20 2019-06-19 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
CN105316404B (zh) * 2015-02-27 2017-02-22 中南大学湘雅二医院 系统性红斑狼疮生物标志物及其诊断试剂盒
KR102632796B1 (ko) 2016-03-10 2024-02-02 비엘라 바이오, 인크. Ilt7 결합 분자 및 이의 사용 방법
CN105567861B (zh) * 2016-03-16 2018-12-14 宫蕊 Ifi27作为冠心病诊断标志物的用途
EA202192176A1 (ru) * 2019-02-15 2022-01-13 Астразенека Аб Нарушения, опосредованные интерфероном i типа
EP4058060A1 (en) 2019-11-11 2022-09-21 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
EP4157873A2 (en) 2020-05-29 2023-04-05 Astrazeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
WO2022106460A2 (en) 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
KR20240000557A (ko) 2021-04-23 2024-01-02 아스트라제네카 아베 피부 홍반 루푸스의 치료
WO2022223714A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Anti-ifnar1 dosing regime for subcutaneous injection
KR20240001704A (ko) 2021-04-23 2024-01-03 아스트라제네카 아베 항-i형 inf 수용체 항체 아니프롤루맙을 이용한 루푸스 신염의 치료
AU2022270101A1 (en) * 2021-05-04 2023-10-05 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
IL308128A (en) 2021-05-12 2023-12-01 Astrazeneca Ab Inhibitor of type 1 interferon receptor spares steroids in patients with systemic lupus erythematosus
EP4377349A1 (en) 2021-07-27 2024-06-05 Astrazeneca AB Treatment of lupus
AU2022359684A1 (en) 2021-10-04 2024-05-09 Astrazeneca Ab Treatment of lupus
WO2024056631A1 (en) 2022-09-14 2024-03-21 Idorsia Pharmaceuticals Ltd S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases
WO2024079241A1 (en) 2022-10-13 2024-04-18 Astrazeneca Ab Treatment of lupus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
WO1984003106A1 (en) 1983-02-04 1984-08-16 Wadley Inst Of Molecular Medic Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US7247425B2 (en) * 1998-01-30 2007-07-24 Evolutionary Genomics, Llc Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CA2518101A1 (en) * 2003-03-03 2005-06-09 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
ES2368737T3 (es) 2003-04-23 2011-11-21 Medarex, Inc. Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
LT2418220T (lt) 2003-12-10 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa antikūnai ir jų panaudojimas
CA2558808A1 (en) * 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
PT2662390T (pt) 2004-06-21 2017-10-09 Squibb & Sons Llc Anticorpos contra recetor 1 do interferão alfa e as suas utilizações
PL2327792T3 (pl) * 2005-08-05 2014-03-31 Genentech Inc Sposoby i kompozycje do wykrywania zaburzeń autoimmunologicznych
WO2007123765A2 (en) * 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
WO2008016356A2 (en) * 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
BRPI0719912A2 (pt) * 2006-12-06 2014-03-04 Medimmune Llc Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico
EP2068924A4 (en) * 2007-05-03 2011-07-20 Medimmune Llc INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
EP2848702A1 (en) * 2008-02-08 2015-03-18 MedImmune, LLC Disease markers and uses thereof
SG190570A1 (en) * 2008-04-21 2013-06-28 Novartis Forschungsstiftung Antiviral therapy
WO2009149319A2 (en) * 2008-06-05 2009-12-10 Wyeth Gene expression profiles associated with asthma exacerbation attacks

Also Published As

Publication number Publication date
CN102753704A (zh) 2012-10-24
HRP20170091T1 (hr) 2017-03-24
WO2011028933A1 (en) 2011-03-10
MX2012002640A (es) 2012-06-25
DK2473636T3 (en) 2017-02-06
PL2473636T3 (pl) 2017-05-31
US20160024205A1 (en) 2016-01-28
SMT201700063B (it) 2017-03-08
US20150191788A1 (en) 2015-07-09
RU2012112802A (ru) 2013-10-10
SI2473636T1 (sl) 2017-04-26
CA2772921A1 (en) 2011-03-10
EP2473636B1 (en) 2016-10-26
PT2473636T (pt) 2017-02-06
KR20120101340A (ko) 2012-09-13
LT2473636T (lt) 2017-02-10
CY1118566T1 (el) 2017-07-12
JP2015147788A (ja) 2015-08-20
AU2010289383A1 (en) 2012-04-19
JP5727484B2 (ja) 2015-06-03
HUE032917T2 (hu) 2017-11-28
AU2010289383B2 (en) 2015-04-16
EP2473636A1 (en) 2012-07-11
BR112012004781A2 (pt) 2017-02-14
EP2473636A4 (en) 2013-02-27
US20120251546A1 (en) 2012-10-04
ME02599B (me) 2017-06-20
JP2013503642A (ja) 2013-02-04
ES2613055T3 (es) 2017-05-22

Similar Documents

Publication Publication Date Title
EP2473636A4 (en) INTERFERON DIAGNOSIS TYPE 1
GB0913345D0 (en) New combination 802
EP2513131A4 (en) NOVEL 3'-DEOXY-3'-METHYLIDENE-L-NUCLEOSIDES
GB0903160D0 (en) Fusebox 4
GB0921324D0 (en) Guttergrow 2
GB0916350D0 (en) Flexi-bend 2000
GB0902804D0 (en) Fusebox 2
GB0901941D0 (en) 1007
GB0916457D0 (en) Concept 36
GB0916471D0 (en) Concept 51
GB0916446D0 (en) Concept 21
GB0916447D0 (en) Concept 22
GB0911961D0 (en) Concept 48
GB0911960D0 (en) Concept 47
GB0916448D0 (en) Concept 23
GB0900055D0 (en) Concept 46
GB0916463D0 (en) Concept 40
GB0916475D0 (en) Concept 54
GB0916449D0 (en) Concept 30
GB0916474D0 (en) Concept 53
GB0916473D0 (en) Concept 52
GB0916450D0 (en) Concept 29
GB0916451D0 (en) Concept 31
GB0916452D0 (en) Concept 32
GB0916453D0 (en) Concept 33